Cargando…

Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study

BACKGROUND: Glioblastoma (GBM) has a poor prognosis, and patients with epidermal growth factor receptor (EGFR) amplification have an even worse prognosis. Nimotuzumab is an EGFR monoclonal antibody thought to play a significant role in the treatment of GBM. This paper presents a retrospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales:	She, Lei, Gong, Xuan, Su, Lin, Liu, Chao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Neuro-Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847561/ https://www.ncbi.nlm.nih.gov/pubmed/36181764 http://dx.doi.org/10.1093/oncolo/oyac202

Ejemplares similares

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study
por: Chen, Jie, et al.
Publicado: (2022)

Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
por: Omuro, Antonio, et al.
Publicado: (2022)

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial
por: Yuan, Jing-Jing, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
por: Attarian, Fahimeh, et al.
Publicado: (2021)

Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
por: Saran, Frank, et al.
Publicado: (2021)

Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
por: Miller, Ryan, et al.
Publicado: (2022)

Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review
por: Su, Jiahao, et al.
Publicado: (2016)

Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases
por: Furtner, Julia, et al.
Publicado: (2017)

Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial
por: Du, Xiao-Jing, et al.
Publicado: (2019)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature
por: Waqar, Mueez, et al.
Publicado: (2022)

COVD-29. CONTINUATION OF TEMOZOLOMIDE CHEMOTHERAPY IN A GLIOBLASTOMA PATIENT AFTER RESOLUTION OF COVID-19 PNEUMONIA
por: Thakkar, Jigisha, et al.
Publicado: (2020)

Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study
por: Wei, Kuo-Chen, et al.
Publicado: (2021)

Venous thromboembolic events in glioblastoma patients: An epidemiological study
por: Eisele, Amanda, et al.
Publicado: (2022)

Immune-checkpoint inhibitors for glioblastoma: what have we learned?
por: Omuro, Antonio
Publicado: (2022)

Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials
por: Du, Chigang, et al.
Publicado: (2016)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
por: Nguyen, Ludovic T., et al.
Publicado: (2013)

Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial
por: Compter, Inge, et al.
Publicado: (2020)

Duplication of the pituitary gland - plus syndrome
por: Sen, Debraj, et al.
Publicado: (2016)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

Nimotuzumab enhances temozolomide‐induced growth suppression of glioma cells expressing mutant EGFR in vivo
por: Nitta, Yusuke, et al.
Publicado: (2016)

Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report
por: Li, Yan, et al.
Publicado: (2022)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients
por: Joo, Jin-Deok, et al.
Publicado: (2012)

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
por: Fulton, Ben, et al.
Publicado: (2017)

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
por: Lim, Michael, et al.
Publicado: (2022)

Challenges Conveying Clinical Equipoise and Exploring Patient Treatment Preferences in an Oncology Trial Comparing Active Monitoring with Radiotherapy (ROAM/EORTC 1308)
por: Sherratt, Frances C., et al.
Publicado: (2020)

Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era
por: Paravati, Anthony J., et al.
Publicado: (2010)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

Glioblastoma post-operative imaging in neuro-oncology: current UK practice (GIN CUP study)
por: Booth, Thomas C., et al.
Publicado: (2020)

Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma
por: Huang, Jianfeng, et al.
Publicado: (2017)

MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab
por: Zhang, Kai-Liang, et al.
Publicado: (2014)

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Clinicogenomic factors and treatment patterns among patients with advanced non–small cell lung cancer with or without brain metastases in the United States
por: Smyth, Emily Nash, et al.
Publicado: (2023)

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
por: Chong, Dawn Q, et al.
Publicado: (2015)

Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2019)

Shear-wave elastography: a new potential method to diagnose ulnar neuropathy at the elbow
por: Paluch, Łukasz, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5uh3tulb8ohoppf7p9un3kjbf6